Yumanity Secures $45M to Identify Drugs for Protein Misfolding-Diseases

Startup company Yumanity Therapeutics has secured a $45M series A financing round to identify drugs for neurodegenerative diseases caused by protein misfolding, including ALS, Alzheimer’s and Parkinson’s disease. Biogen and Sanofi-Genzyme BioVentures are among the investors in the company, which was launched in 2014 by former Onyx CEO Tony Coles and protein folding scientific leader Susan Lindquist (see Dec 2014 news). The company’s discovery platform was originally developed in Lindquist’s laboratory and combines parallel screening in yeast cells and human patient neurons to identify drugs that prevent protein misfolding and aggregation.

Click here to read more.

disease-ad disease-als disease-ftd disease-pd topic-preclinical topic-randd
Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail